Skip to main content
Top
Published in: BMC Infectious Diseases 1/2021

Open Access 01-12-2021 | Malaria | Research

The association between malaria prevalence and COVID-19 mortality

Author: Michael U. Anyanwu

Published in: BMC Infectious Diseases | Issue 1/2021

Login to get access

Abstract

Background

The number of persons infected with COVID-19 continues to increase with deaths reported daily across the globe. High income countries such as the US, the UK, Italy and Belgium have reported high COVID-19 related deaths but low-and-middle-income countries have recorded fewer deaths despite having poor healthcare system. This study aimed to investigate the association between malaria prevalence and COVID-19 mortality.

Methods

An ecological study was conducted with data from 195 countries. Spearman’s correlation was used to test the association between the population variables and COVID-19 mortality. Generalized linear model with Poisson distribution was used to determine the significant predictors of COVID-19 mortality.

Results

There was a significant positive correlation between median age, life expectancy, 65+ mortality and COVID-19 mortality while malaria prevalence, sex ratio and cardiovascular mortality were negatively correlated with COVID-19 mortality. Malaria prevalence, life expectancy and mortality rate were significant on multivariate regression analysis.

Conclusion

The results of this study support the hypotheses that there are reduced COVID-19 deaths in malaria endemic countries, although the results need to be proved further by clinical trials.
Literature
6.
go back to reference Mitsuyoshi U, Katharina O, Yasutaka H, Taisuke A. BCG vaccination and mortality of COVID-19 across 173 countries: an ecological study. Int J Environ Res Public Health. 2020;17(5589):5589. Mitsuyoshi U, Katharina O, Yasutaka H, Taisuke A. BCG vaccination and mortality of COVID-19 across 173 countries: an ecological study. Int J Environ Res Public Health. 2020;17(5589):5589.
7.
go back to reference Murray CJ, Lopez AD, Chin B, Feehan D, Hill KH. Estimation of potential global pandemic influenza mortality on the basis of vital registry data from the 1918–20 pandemic: a quantitative analysis. Lancet. 2006;368:2211–8.CrossRef Murray CJ, Lopez AD, Chin B, Feehan D, Hill KH. Estimation of potential global pandemic influenza mortality on the basis of vital registry data from the 1918–20 pandemic: a quantitative analysis. Lancet. 2006;368:2211–8.CrossRef
8.
go back to reference Yakubu L. Africa’s low COVID-19 mortality rate: a paradox. Int J Infect Dis. 2020;102:118–22. Yakubu L. Africa’s low COVID-19 mortality rate: a paradox. Int J Infect Dis. 2020;102:118–22.
9.
go back to reference Deng G, Yin M, Chen X, Zeng F. Clinical determinants for fatality of 44,672 patients with COVID-19. Crit Care. 2020;24:179.CrossRef Deng G, Yin M, Chen X, Zeng F. Clinical determinants for fatality of 44,672 patients with COVID-19. Crit Care. 2020;24:179.CrossRef
10.
go back to reference Azhar M, Kiran K, Manish T, Rupesh S, Asif M. Comparative analysis revealed reduced spread of COVID-19 in malaria endemic countries. medRxiv. 2020. Azhar M, Kiran K, Manish T, Rupesh S, Asif M. Comparative analysis revealed reduced spread of COVID-19 in malaria endemic countries. medRxiv. 2020.
11.
go back to reference World Health Organization W. World malaria report 2020: 20 years of global progress and challenges. Geneva: World Health Organization; 2020.CrossRef World Health Organization W. World malaria report 2020: 20 years of global progress and challenges. Geneva: World Health Organization; 2020.CrossRef
14.
go back to reference Hussein MIH, Albashir AAD, Elawed OAMA. Malaria and COVID-19: unmasking their ties. Malar J. 2020;19:457.CrossRef Hussein MIH, Albashir AAD, Elawed OAMA. Malaria and COVID-19: unmasking their ties. Malar J. 2020;19:457.CrossRef
15.
go back to reference Pietro EN, Matteo N. Global spread of coronavirus disease 2019 and malaria: An epidemiological paradox in the early stage of a pandemic. J Clin Med. 2020;8(4):1138. Pietro EN, Matteo N. Global spread of coronavirus disease 2019 and malaria: An epidemiological paradox in the early stage of a pandemic. J Clin Med. 2020;8(4):1138.
16.
go back to reference Schofield L, Mueller I. Clinical immunity to malaria. Curr Mol Med. 2006;6(2):205–21.CrossRef Schofield L, Mueller I. Clinical immunity to malaria. Curr Mol Med. 2006;6(2):205–21.CrossRef
17.
go back to reference Bustinduy AL, et al. Age strattified profiles of serum IL-6, IL-10, and TNF-alpha cytokines among Kenyan children with schistosoma haematobium, plasmodium falciparum and other chronic parasitic co-infections. Am J Trop Med Hyg. 2015;95(5):945–51.CrossRef Bustinduy AL, et al. Age strattified profiles of serum IL-6, IL-10, and TNF-alpha cytokines among Kenyan children with schistosoma haematobium, plasmodium falciparum and other chronic parasitic co-infections. Am J Trop Med Hyg. 2015;95(5):945–51.CrossRef
18.
go back to reference Teo TH, et al. Plasmodium co-infection protects against chikungunya virus induced pathogies. Nat Commun. 2018;2018(9):1. Teo TH, et al. Plasmodium co-infection protects against chikungunya virus induced pathogies. Nat Commun. 2018;2018(9):1.
19.
go back to reference Hoffmann M, Kleine-Weber H, Kruger N, Muller M, Drosten C, Pohlmann S. The novel coronavirus 2019 uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv. 2020. Hoffmann M, Kleine-Weber H, Kruger N, Muller M, Drosten C, Pohlmann S. The novel coronavirus 2019 uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv. 2020.
20.
go back to reference Rasti N, Wahlgren M, Chen Q. Molecular aspects of malaria pathogenesis. FEMS ImmunolMed Microbiol. 2004;41:9–26.CrossRef Rasti N, Wahlgren M, Chen Q. Molecular aspects of malaria pathogenesis. FEMS ImmunolMed Microbiol. 2004;41:9–26.CrossRef
21.
go back to reference Dhangadamajhi G, Mohapatra BN, Kar SN, Ranjit M. Gene polymorphisms in angiotensin 1 converting enzyme (ACE1/D) and angiotensin 2 converting enzyme (ACE2) protect against cerebral malaria in Indian adults. Infect Genet Evol. 2010;10:337–41.CrossRef Dhangadamajhi G, Mohapatra BN, Kar SN, Ranjit M. Gene polymorphisms in angiotensin 1 converting enzyme (ACE1/D) and angiotensin 2 converting enzyme (ACE2) protect against cerebral malaria in Indian adults. Infect Genet Evol. 2010;10:337–41.CrossRef
22.
go back to reference Strayer D, Dickey R, Carter W. Sensitivity of SARS/MERS CoV to interferons and other drugs based on achievable serum concentrations in humans. Infect Disord Drug Targets. 2014;14:37–43.CrossRef Strayer D, Dickey R, Carter W. Sensitivity of SARS/MERS CoV to interferons and other drugs based on achievable serum concentrations in humans. Infect Disord Drug Targets. 2014;14:37–43.CrossRef
23.
go back to reference Fauci AS, Lane HC, Redfield RR. COVID-19—navigating the uncharted. N Engl J Med. 2020;382:1268–9.CrossRef Fauci AS, Lane HC, Redfield RR. COVID-19—navigating the uncharted. N Engl J Med. 2020;382:1268–9.CrossRef
24.
go back to reference Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19. N Engl J Med. 2020;383:517–25.CrossRef Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19. N Engl J Med. 2020;383:517–25.CrossRef
26.
go back to reference Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today’s diseases. Lancet Infect Dis. 2003;3:722–7.CrossRef Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today’s diseases. Lancet Infect Dis. 2003;3:722–7.CrossRef
27.
go back to reference Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69.CrossRef Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69.CrossRef
28.
go back to reference Francesco DG, Claudia M, Pietro L, Damiano P, Giovanni P. Malaria and COVID-19: common and different findings. Trop Med Infect Dis. 2020;5:141.CrossRef Francesco DG, Claudia M, Pietro L, Damiano P, Giovanni P. Malaria and COVID-19: common and different findings. Trop Med Infect Dis. 2020;5:141.CrossRef
Metadata
Title
The association between malaria prevalence and COVID-19 mortality
Author
Michael U. Anyanwu
Publication date
01-12-2021
Publisher
BioMed Central
Keywords
Malaria
COVID-19
Published in
BMC Infectious Diseases / Issue 1/2021
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-021-06701-8

Other articles of this Issue 1/2021

BMC Infectious Diseases 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine